Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dianne Carey

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Journal of the International AIDS Society|November 14, 2014
Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 studyDianne Carey
Journal of HIV Therapy|July 4, 2003
Once-daily therapiesDianne Carey
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 13, 2002
Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatographyJohn Ray, Edna Pang, Dianne Carey
AIDS Reviews|July 11, 2008
Restorative interventions for HIV facial lipoatrophyDianne Carey, Steven Liew, Sean Emery
The Journal of Antimicrobial Chemotherapy|June 18, 2010
Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trialsDianne Carey, Janaki Amin, Mark Boyd, et al.
AIDS (London, England)|July 30, 2005
Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trialDianne Carey, Handan Wand, Allison Martin, et al.
AIDS (London, England)|September 24, 2009
Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trialTim R H Read, Dianne Carey, Patrick Mallon, et al.
Therapeutic Drug Monitoring|September 28, 2017
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 StudyAlieu B Amara, Laura J Else, Dianne Carey, et al.
AIDS Research and Human Retroviruses|October 27, 2007
Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudyRaffaella Bucciardini, Vincenzo Fragola, Maurizio Massella, et al.
Antiviral Therapy|March 9, 2005
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophyJason C Kovacic, Allison Martin, Dianne Carey, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Journal of the International AIDS Society|November 14, 2014
Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 studyDianne Carey
Journal of HIV Therapy|July 4, 2003
Once-daily therapiesDianne Carey
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|July 13, 2002
Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatographyJohn Ray, Edna Pang, Dianne Carey
AIDS Reviews|July 11, 2008
Restorative interventions for HIV facial lipoatrophyDianne Carey, Steven Liew, Sean Emery
The Journal of Antimicrobial Chemotherapy|June 18, 2010
Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trialsDianne Carey, Janaki Amin, Mark Boyd, et al.
AIDS (London, England)|July 30, 2005
Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trialDianne Carey, Handan Wand, Allison Martin, et al.
AIDS (London, England)|September 24, 2009
Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trialTim R H Read, Dianne Carey, Patrick Mallon, et al.
Therapeutic Drug Monitoring|September 28, 2017
Comparison of Dried Blood Spots Versus Conventional Plasma Collection for the Characterization of Efavirenz Pharmacokinetics in a Large-Scale Global Clinical Trial-The ENCORE1 StudyAlieu B Amara, Laura J Else, Dianne Carey, et al.
AIDS Research and Human Retroviruses|October 27, 2007
Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudyRaffaella Bucciardini, Vincenzo Fragola, Maurizio Massella, et al.
Antiviral Therapy|March 9, 2005
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophyJason C Kovacic, Allison Martin, Dianne Carey, et al.
Pageof 2